New board member for Siegfried
At the Shareholders’ Meeting scheduled for 18 April 2013, the Board of Directors of Siegfried Holding AG will propose the appointment to the Board of Colin Bond, Chief Financial Officer of Evotec AG.
Colin Bond, 52, is a citizen of Great Britain and Switzerland. In 2010, he joined Hamburg-based Evotec AG as group Chief Financial Officer and member of the management board. The company is listed on the Frankfurt Stock Exchange as part of TecDax and provides a wide range of research and development services in the field of pharmaceutical ingredients. Following career stations as a pharmacist, chartered accountant and management consult-ant, he worked for 25 years as Chief Financial Officer for several international companies in various industries, of which 11 years for Great Lakes Chemical Corporation, today Chemtura, a US-based global specialty chemicals company.
Colin Bond holds a university degree in pharmacy from the University of Aston, Birmingham, and a MBA degree from London Business School.
Most read news
Other news from the department people

Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.